Alliance and Collaboration - Additional Information (Details) € in Millions, $ in Millions								1 Months Ended	3 Months Ended			12 Months Ended
	Feb. 26, 2024 USD ($)	Feb. 23, 2024 USD ($)	Feb. 23, 2024 EUR (€)	Jan. 24, 2024	Oct. 12, 2023 product	Dec. 28, 2022	May 07, 2018 USD ($)	Dec. 31, 2023 USD ($)	Mar. 31, 2024 USD ($)	Mar. 31, 2024 EUR (€)	Mar. 31, 2023 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Feb. 23, 2024 EUR (€)	Dec. 05, 2023 USD ($)
License Agreement with Orion Corporation
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement term						8 years
Collaborative arrangement renew for successive term						2 years
Collaborative arrangement license revenue agreement									$ 0.6		$ 0.6
License Agreement with Orion Corporation | Accounts Payable and Accrued Liabilities
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Deferred income								$ 7.8	10.7			$ 7.8
License Agreement with Orion Corporation | Other long-term liabilities
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Deferred income								4.7	1.2			4.7
ONGENTYS® License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, medical and marketing activities															$ 6.0
Collaborative arrangement non-refundable license fee								$ 12.5
Collaborative arrangement non-refundable license fee, amortization period								8 years
License supply agreement, potential future milestone payments								$ 22.5
License Agreement with Zambon Biotech
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement term		15 years	15 years
Collaborative arrangement renew for successive term		2 years	2 years
License supply agreement, potential future milestone payments		$ 77.2	€ 71.5
Notice period		1 year	1 year
Nonrefundable license fee received, amount		$ 5.4												€ 5.0
Collaborative arrangement net revenue agreement									3.5	€ 3.2
Biosimilar Licensing and Supply Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License supply agreement, potential future milestone payments												66.0
Other long term liabilities							$ 78.3
Collaborative arrangement maximum milestone paid												2.5	$ 26.5
Estimated useful life (in years)													7 years
Collaborative arrangement aggregate sales-based milestone payment									9.5
Collaborative arrangement, number of products | product					2
Collaborative arrangement upfront payment									$ 3.0			2.5
Biosimilar Licensing and Supply Agreement | Development Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License supply agreement, potential future milestone payments												3.5
Biosimilar Licensing and Supply Agreement | Regulatory Approval
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License supply agreement, potential future milestone payments												$ 15.0
Biosimilar Licensing and Supply Agreement | Achievement of Cumulative Net Sales
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License supply agreement, potential future milestone payments											$ 47.5
Knight Therapeutics International S.A. License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement term				15 years
Collaborative arrangement renew for successive term				2 years
License supply agreement, potential future milestone payments	$ 10.5
Notice period				1 year
Nonrefundable license fee received, amount	$ 1.0